Mark Elliott Boulding sold $214k of PTCT
EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 3,375 shares at an average of $63.43, traded Oct 7, 2025, filed Oct 9, 2025.
Score components
- +15RoleOfficer
- +12Trade size$214k at market
- 0Share of holdings soldSold 3.1% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001578852-25-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | MOption exercise Common Stock10b5-1 | +3,375 | $38.10 | $129k | 107,276 | Oct 9, 2025 |
| Oct 7, 2025 | SOpen-market sale Common Stock10b5-1 | -1,757 | $62.89 | $110k | 105,519 | Oct 9, 2025 |
| Oct 7, 2025 | SOpen-market sale Common Stock10b5-1 | -1,306 | $63.80 | $83k | 104,213 | Oct 9, 2025 |
| Oct 7, 2025 | SOpen-market sale Common Stock10b5-1 | -312 | $64.97 | $20k | 103,901 | Oct 9, 2025 |
| Oct 7, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,375 | $0.00 | $0 | 3,376 | Oct 9, 2025 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 31Weak | PTC THERAPEUTICS, INC. | Matthew B. Klein CHIEF EXECUTIVE OFFICER | $171k 2,662 shares | -1% | |
| 43Moderate | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $253k 3,989 shares | -59% | |
| 35Weak | PTC THERAPEUTICS, INC. | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | $634k 10,000 shares | -11% | |
| 22Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $210k 3,019 shares | -3% | |
| 22Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $216k 3,121 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.